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Introduction 
Two population of multipotent progenitors reside in 
bone  marrow  (BM):  Hematopoietic  stem  cells 
(HSCs)  and  mesenchymal  stem  cells  (MSCs).
1,2  In 
bone  marrow  MSCs  are  able  to  support 
hematopoiesis by releasing stromal-derived factor-1, 
Flt-3 ligand and stem cell factor.
3 This subset of cells 
can migrate to damaged tissues
4 and differentiate into 
at  least  three  lineages:  osteoblasts,  adipocytes,  and 
chondrocytes.
5-7  Trilineage  differentiation  is 
considered  as  minimal  criteria  for  their 
multipotency.
8,9 
This  class  of  multipotent  progenitors  first  were 
recognized by Friedenstein et al in France in 1968.
10 
Friedenstein  and  his  colleges  described  an 
undifferentiated heterogeneous subset of cells which 
were  spindle-shaped,  plastic-adherent,  non-
phagocytic with ﬁbroblast-like morphology.
11,12 Later 
in 1974, when they cultured a small amount of these 
cells  in  basal  cell  culture  medium  and  saw  their 
ability  to  generating  clonal  ﬁbroblast-like  colonies, 
they recognized that these cells had a high potential 
of  proliferatition,  therefore  they  named  them 
ﬁbroblast colony-forming cells (CFU-F),
11 afterward 
these cells entitled as mesenchymal stem cells. 
In addition to bone marrow, MSCs can be identified 
in  other  tissues  like  fat,  muscle,  perichondrium, 
dental pulp and fetal tissues including BM, spleen, 
lung and liver;
13-15 as well as in other animals like 
mouse,  rat,  cat,  dog  and  horse.
16  For  experimental 
and therapeutic purposes, MSCs are usually isolated 
from  human  bone  marrow  and  fat.
17,18  Although 
MSCs  are  characterized  by  their  ability  for 
differentiation  into  bone,  fat,  and  cartilage,
5,6  they 
can  also  differentiate  into  other  tissues  including 
tendon,  muscle,  nerve,  liver,  kidney,  pancreas  and 
skin.
16,19  
Bone  marrow-derived  MSCs  characteristically  lack 
hematopoietic  antigens  including  CD45,  CD34, 
CD133,  CD14,  and  MHC  class  II  as  well  as 
endothelial antigens including CD80, CD34, CD31, 
vWF. On the other hand, they express stromal cell 
surface  markers  and  adhesion  molecules  such  as 
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MSCs  are  multipotent  progenitors  which  reside  in  bone  marrow.  They  support 
hematopoietic stem cells homing, self renewal and differentiation in bone marrow. They 
can also differentiate into osteoblasts, adipocytes, chondrocytes, myocyates and many 
other tissues. In vivo, when trauma happens, MSCs operate cell renewal and migrate to 
the damaged tissues to regenerate that injury. In vitro, MSCs are able to proliferate and 
differentiate to a variety of cell lineages. This makes them a very hopeful tool for cell-
based regenerative therapy for large bone defects, maxillofacial skeletal reconstruction, 
cardiovascular and spinal cord injury and so many other defects. The most important 
characteristic that make MSCs an excellent tool for cell replacement is their ability to 
escape  from  immune  rejection.  For  therapeutic  purposes  they  usually  isolated  from 
human bone marrow or fat and they should proliferate in order to reach an adequate 
number for implantation. Conventionally DMEM medium supplemented with 10% FBS 
is used for their expansion, but currently autologous platelet rich products are replaced 
FBS.  Platelet  granules  contain  so  many  growth  factors  that  can  support  MSCs 
proliferation.  
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CD105,  CD106,  CD166,  CD90,  CD73,  CD44, 
CD140b, CD9, CD10, CD13, and CD29.
1,20,21 
MSCs have a significant role in lymphopoiesis and 
myelopoiesis  and  show  extensive 
immunomodulatory  properties  too.  MSCs  arrest  B 
and T lymphocytes in G0/G1 phase of the cell cycle, 
thus  inhibit  their  responses.  MSCs  can  prevent 
monocytes  from  their  function  as  an  antigen-
presenting  cell  (APC).  Moreover,  they  improve 
regulatory  T  cell  expansion.
22,23  In  vitro,  MSCs 
release IL-6, IL-7, IL-8, IL-11, IL-12, IL-14, IL-15.
24 
Self-renewal potential
25 and multipotency are MSCs's 
hallmarks.
12  Bone  marrow-derived  mesenchymal 
stem  cells  (BM-MSCs)  are  simply  isolated  from  a 
small  aspirate  of  bone  marrow  and  are  able  to 
proliferate  ex  vivo  and  generate  a  variety  of  cell 
types.
26  In  vitro,  MSCs  can  proliferate  and 
differentiate  into  a  desired  cell  lineage  using  a 
specific medium
27 with a mixture of growth factors 
and other elements.
28 For instance, if MSCs cultured 
in  the  presence  of  dexamethasone,  h-
glycerophosphate  and  ascorbic  acid,  they  will 
differentiate  to  osteoblasts.
26  Moreover,  following 
implantation of cultured and expanded MSCs into the 
damaged tissues, they  are able  to differentiate  into 
mature cells.
28 Additionally, MSCs which undergoes 
genetic  modification  in  vitro  can  release  particular 
growth  factors  and  cytokines  subsequent  to  tissue 
implantation.
29 
These  last  characteristics  make  MSCs  a  very 
promising  candidate  for  clinical  applications  of 
autograft regenerating therapies in tissues damaged 
by  trauma,  aging  or  acute  and  chronic  diseases.
28 
Furthermore, MSCs are appropriate therapeutic tool 
to  repair  large  bone  defects
30,31  and  maxillofacial 
skeletal reconstruction;
32 as well as cell replacement 
therapy  in  diabetes,
33  spinal  cord  injury,
34 
cardiovascular,
35  neurological,
34  pulmonary
36  and 
immunological  diseases.
23  Over  and  above,  MSCs 
have a supportive function in co-transplantation with 
hematopoietic  stem  cells
17,18,37,38  by  secreting 
stromal-derived factor-1
3 Flt-3 ligand and stem cell 
factor,
24 along with expressing extra-cellular matrix 
proteins  including  fibronectin,  Laminin  and 
vimentin
39 which have a crucial role in HSC homing 
in bone marrow niche.
38,40 One of the most important 
properties that make MSCs an excellent tool for cell-
based therapeutic strategies is their ability to escape 
from immune rejection; therefore, HLA-matching is 
not that much important for  their implantation and 
HLA-mismatched donors can be selected too.
22,23 
MSCs  comprise  a  remarkably  rare  population  of 
unfractionated  bone  marrow  and  most  tissues  like 
fat.
23 It is absolutely difficult to determine the exact 
number of MSCs in bone marrow, due to different 
techniques  of  bone  marrow  aspiration  and  MSC 
isolation.  However,  it  is  estimated  that  MSCs  are 
about  0.001%  of  mononucleated  cells  in  BM,
30 
although the number of them decrease with age.
41 For 
clinical  purposes  we  need  a  large-scale  of  MSCs, 
therefore  ampliﬁcation  procedure  must  be  done  to 
generate plenty of cells. 
Optimized condition for MSCs expansion consist of 
low  glucose  α-DMEM (Dulbecco's Modified  Eagle 
Medium)  as  basal  media,  10%  fetal  bovine  serum 
(FBS)  as  protein  supplement  supporter  and 
penicillin/streptomycin solution to prevent  bacterial 
contaminations.  As  recommended  by  Meuleman  et 
al,  enriching  media  with  some  synthetic  growth 
factors  or  anti-oxidants  will  decrease  the  instance 
between  MSCs  isolation  and  clinical  application.
42 
Nowadays, some guidelines suggest to avoid utilize 
animal derivatives like FBS, synthetic growth factors 
and allogeneic materials for  therapeutic application 
since they raise the risks of pathogen transmission, 
infection and immune responses. Hence, autologous 
alternatives like platelet lysate(PL),
43,44 platelet rich 
plasma(PRP)
45-47  and  platelet  rich  fibrin(PRF)
48-50 
can be  employed. These three products are rich  in 
platelets
51 which contain a variety of growth factors 
including  platelet-derived  growth  factor  (PDGF), 
ﬁbroblast  growth  factor  (FGF),  insulin-like  growth 
factor  (IGF),  transforming  growth  factor  (TGFb), 
platelet  factor  4  (PF-4),  and  platelet-derived 
epidermal  growth  factor  (PDEGF).
52  These  growth 
factors enhance and accelerate MSCs proliferation in 
vitro and in vivo.
45,53 
 
Conclusion  
MSCs are capable to expand in vitro and differentiate 
into a variety of cell lineages either in vitro or in vivo 
after  implantation.
4-6  As  a  result  they  can  be 
considered  as  a  hopeful  tool  for  cell-based 
replacement therapy.
26-33 For this purpose, first they 
should  be  expanded  in  vitro  to  reach  an  adequate 
number for  clinical approaches.  Conventionally  we 
use  FBS  for  their  proliferation  in  cell  culture 
medium.
39  Since  FBS  is  a  bovine  derived  additive 
and may cause infectious, prion transmission or may 
raise immune responses; it cannot be an appropriate 
supplement  for  cell  culture  medium  when 
transplantation  expanded  MSCs  is  our  final 
intention.
40  Because  platelets  have  a  variety  of 
growth  factors  which  may  enhance  MSCs 
proliferation,  platelet  rich  products  would  be  an 
excellent  alternative  for  FBS  replacement.
49 
Nowadays  using  autologous  platelet  rich  products 
including  platelet  lysate(PL),
43,44  platelet  rich 
plasma(PRP)
45-47 and platelet rich fibrin(PRF)
48-50 for 
MSCs expansion become more general.
53 Employing 
autologous  platelet  rich  products  for  MSCs 
expansion is a convenient, non-toxic, safe and cheap 
therapeutic  method  that  promotes  using  MSCs  for 
cell therapy. 
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